8QQ.F ABCELLERA BIOLOGICS

Healthcare Biotechnology Frankfurt Exchange
11.84 EUR
Close of Nov 11, 2026
2.49 12.96
Market cap
EUR 3.87B
P/E
-
P/B
3.75x
ROE
-17.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 8QQ.F undervalued?

Graham number

The Graham number of ABCELLERA BIOLOGICS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ABCELLERA BIOLOGICS fundamental analysis

No fundamental analysis for ABCELLERA BIOLOGICS yet.

ABCELLERA BIOLOGICS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ABCELLERA BIOLOGICS

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The …

Full company profile